Complement component c3 irna compositions and methods of use thereof
US-2026049312-A1 · Feb 19, 2026 · US
This page is not indexed by search engines while we improve data quality.
Keating Mark patents
Keating Mark is listed as an inventor on 25 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Keating Mark |
| Total patents | 25 |
| First publication | Oct 29, 2020 |
| Latest publication | Feb 19, 2026 |
Notable patents
Publications ranked by popularity score, then publication date.
Coagulation factor V (F5) iRNA compositions and methods of use thereof
US-12473550-B2 · Nov 18, 2025 · US
Modified double stranded oligonucleotides
US-2025283071-A1 · Sep 11, 2025 · US
Complement component C3 iRNA compositions and methods of use thereof
US-12365896-B2 · Jul 22, 2025 · US
Coagulation factor V (F5) iRNA compositions and methods of use thereof
US-12331297-B2 · Jun 17, 2025 · US
Complement component C3 iRNA compositions and methods of use thereof
US-12258565-B2 · Mar 25, 2025 · US
Implantable and continuous multi-analyte monitor (mam) sensor
US-2024374214-A1 · Nov 14, 2024 · US
Atxn2 irna compositions and methods of use thereof for treating or preventing atxn2-associated neurodegenerative diseases
US-2024294906-A1 · Sep 5, 2024 · US
COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US-2024218366-A1 · Jul 4, 2024 · US
Complement component c3 irna compositions and methods of use thereof
US-2024209369-A1 · Jun 27, 2024 · US
Recent patents
Latest publications not already listed above.
COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US-2024209358-A1 · Jun 27, 2024 · US
TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES
US-2024200061-A1 · Jun 20, 2024 · US
COAGULATION FACTOR X (F10) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US-2024117348-A1 · Apr 11, 2024 · US
mRNA-mediated immunization methods
US-11878060-B2 · Jan 23, 2024 · US
TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES
US-2023304002-A1 · Sep 28, 2023 · US
Compositions and methods for silencing myoc expression
US-2023295622-A1 · Sep 21, 2023 · US
COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING COMPLEMENT COMPONENT C3-ASSOCIATED DISEASES
US-2023272382-A1 · Aug 31, 2023 · US
Compositions and methods for silencing vegf-a expression
US-2023136787-A1 · May 4, 2023 · US
Complement component c3 irna compositions and methods of use thereof
US-2022364088-A1 · Nov 17, 2022 · US
TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES
US-2022333104-A1 · Oct 20, 2022 · US
Diagnostic tool based health management system
US-2022142485-A1 · May 12, 2022 · US
AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF
US-2022002724-A1 · Jan 6, 2022 · US
Mrna-mediated immunization methods
US-2021283262-A1 · Sep 16, 2021 · US
Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof
US-11034957-B2 · Jun 15, 2021 · US
AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF
US-2020339991-A1 · Oct 29, 2020 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Alnylam Pharmaceuticals Inc | 21 |
| Novartis Ag | 2 |
| Univ California | 2 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| C12N2310/315 | 21 |
| C12N15/113 | 21 |
| C12N2310/14 | 20 |
| C12N2310/321 | 18 |
| C12N2310/322 | 17 |